Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 9/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4206556 | 0.98 | NISCH (0.97) | NISCHCYP1A2ALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL8195760 | 0.88 | NISCH (0.78) | NISCHCYP1A2ALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL8196401 | 0.86 | NISCH (0.74) | NISCHCYP1A2ALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL8320468 | 0.83 | NISCH (0.69) | NISCHCYP1A2ALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL6820930 | 0.83 | NISCH (0.70) | NISCHCYP1A2ALDH1A1HSD17B10CYP2D6 | |
| Hydrochloric Acid SCHEMBL7735685 | 0.82 | NISCH (0.68) | NISCHCYP1A2ALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL6824262 | 0.76 | PRMT1 (0.61) | NISCHCYP1A2ALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL6820853 | 0.76 | PRMT1 (0.61) | NISCHCYP1A2ALDH1A1HSD17B10CYP2D6 | |
| SCHEMBL6824770 | 0.76 | NISCH (0.60) | NISCHCYP1A2ALDH1A1HSD17B10CYP2D6 | |
| Hydrochloric Acid SCHEMBL7736303 | 0.75 | NISCH (0.58) | NISCHCYP1A2ALDH1A1HSD17B10CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104473932-B | Treat the pharmaceutical composition of inflammation of the central nervous system demyelinating disease and its purposes of administering drug combinations | 温州医科大学附属第医院 | 2017-06-20 | — | — | CN | claimed |
| CN-104473932-A | Pharmaceutical composition for treating central nervous system inflammatory demyelinating diseases and application of pharmaceutical composition in combined administration | FIRST AFFILIATED HOSPITAL WENZHOU MEDICAL UNIV | 2015-04-01 | — | — | CN | claimed |
| CN-104069102-A | Application of 2-(2-benzofuran group)-2-imidazolidine in preparing medicine for regulating interleukin-17 | ZHENG RONGYUAN | 2014-10-01 | — | — | CN | claimed |
| US-8691859-B2 | Broad spectrum antibacterial compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2014-04-08 | — | — | US | claimed |
| JP-4728257-B2 | — | — | 2011-07-20 | — | — | JP | claimed |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | BAVARI SINA | 2011-04-14 | — | — | US | claimed |
| EP-1945209-A2 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | United States Government As Represented By The Secretary of The United States Army And The U.S. Army Medical Research & Materiel Command (US) | 2008-07-23 | — | — | EP | claimed |
| WO-2008041966-A2 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE SECRETARY OF THE UNITED STATES ARMY AND THE U.S. ARMY MEDICAL RESEARCH & MATERIEL COMMAND (US) | 2008-04-10 | — | — | WO | claimed |
| US-20080027140-A1 | Combinations of Serotonin Reuptake Inhibitors and Imidazoline I 2 Agonists | MERCK PATENT GMBH (DE) | 2008-01-31 | — | — | US | claimed |
| US-20070112048-A1 | Broad Spectrum Antibacterial Compounds | U.S. ARMY MEDICAL RESEARCH AND MATERIEL COMMAND | 2007-05-17 | — | — | US | claimed |
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ARMY, UNITED STATES | 2007-05-17 | — | — | US | claimed |
| EP-1708754-A2 | COMBINATIONS OF SEROTONIN REUPTAKE INHIBITORS AND IMIDAZOLINE-I sb 2 /sb -AGONISTS | MERCK PATENT GmbH (DE) | 2006-10-11 | — | — | EP | claimed |
| WO-2005067969-A2 | COMBINATIONS OF SEROTONIN REUPTAKE INHIBITORS AND IMIDAZOLINE-I2-AGONISTS | MERCK PATENT GMBH (DE) | 2005-07-28 | — | — | WO | claimed |
| EP-4684600-A1 | LIGHTING EFFECTS | Apple Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| WO-2024197092-A1 | LIGHTING EFFECTS | APPLE INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| US-20240091227-A1 | Use Of 2-Phenyl-6-(1H-Imidazol-1-YL) Quinazoline For Treating Neurodegenerative Diseases, Preferably Alzheimer's Disease | Rottapharm Biotech Srl (IT) | 2024-03-21 | — | — | US | disclosed |
| US-5017584-A | Antidepressant 2-(4,5-dihydro-1H-imidazolyl)-dihydro-1H-indoles, -1,2,3,4-tetrahydroquinolines and -1H-indoles, and methods of use thereas | STERLING DRUG INC. (US) | 1991-05-21 | — | — | US | disclosed |
| EP-0071368-B1 | IMIDAZOLINE DERIVATIVES | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1985-04-17 | — | — | EP | disclosed |
| US-4411908-A | ANTIMIGRAINE, ANTIDEPRESSANTS | RECKITT & COLMAN PRODUCTS LIMITED (GB) | 1983-10-25 | — | — | US | disclosed |
| EP-0071368-A1 | Imidazoline derivatives | RECKITT AND COLMAN PRODUCTS LIMITED (GB) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112048-A1 | Broad Spectrum Antibacterial Compounds | MPO, CAT, LPO | NISCH 33/4885CYP1A2 1275/4885ALDH1A1 349/4885 |
| US-20070112049-A1 | nonpeptidic inhibitors of Botulinum neurotoxin A metalloprotease activity, such as 2-[4-(4-carbamimidoylphenoxy)phenyl]-1H-indole-5-carboximidamide, used for treating, inhibiting or preventing intoxication caused by bacteria | ACHE, CTRL, MMP2 | NISCH 181/4885CYP1A2 1708/4885ALDH1A1 1028/4885 |
| US-20110086877-A1 | Small Molecule Inhibitors of Botulinum Neurotoxins | ACHE, MMP2, TIMP3 | NISCH 268/4885CYP1A2 1858/4885ALDH1A1 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.